To hear about similar clinical trials, please enter your email below
Trial Title:
Follow up After TACE by Elastography and Color Doppler.
NCT ID:
NCT06070623
Condition:
Hepatocellular Carcinoma
Conditions: Official terms:
Carcinoma, Hepatocellular
Conditions: Keywords:
TACE
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Device
Intervention name:
US
Description:
We use elastography and color Doppler from US machine and compare results with CT
Other name:
CT
Summary:
To determine accuracy of elastography and color Doppler in follow up of patients with HCC
after TACE comparing with modified RECIST criteria.
Detailed description:
The incidence of liver cancer is one of the highest in the world. In Egypt HCC is the
forth common cancer and represents up to 90% of all liver malignancies. Where it is
responsible for 33.63% and 13.54% of all cancers in males and females respectively.
Transarterial chemoembolization (TACE) is recommended as the first-line treatment in
early stage patients with hepatocellular carcinoma (HCC) or as a palliative treatment
modality in advanced patients with unresctable tumor which was known to increase survival
rate. However, tumor control usually requires multiple TACE interventions due to the
presence of residual and recurrent lesions.
Currently the Response Evaluation Criteria in Solid Tumors (RECIST) guideline was
proposed as a method for measuring treatment response based on tumor shrinkage, which is
a valuable measure of antitumor activity of cytotoxic drugs, Which adapted the concept of
viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced MSCT
abdomen.
Elastography can provide information about tumor stiffness to predict tumor response
after TACE and detect any residual or recurrence.
We also use color Doppler in follow up to detect changes in portal pressure and hepatic
artries hemodynamics of HCC patients after TACE. Mainly we search for changes in portal
vein velocity {PVVel}, hepatic artery resistive index {HARI} and hepatic artery
pulsitality index {HAPI}.
Criteria for eligibility:
Study pop:
Patients with hepatic focal lesion , which is eligable to trans arterial
chemoebmolization.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- All patients with hepatocellular carcinoma underwent TACE in South Egypt cancer
institute.
Exclusion Criteria:
- Patients with liver metastases.
- Patients with hepatic or perihepatic inflammations.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Start date:
November 1, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06070623
